Resources
38 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 2/23/2024 (updated 3/28/2024)
his study assessed the degree in which health care professionals who were practicing within primary care or were likely to come in contact with patients with opioid use disorder (OUD) were endorsing misinformation about buprenorphine and if this affected their willingness to care for patients with OUD.
Posted 10/19/2023 (updated 4/11/2024)
Implementation IV grantees with tools and strategies
Posted 7/21/2023 (updated 3/28/2024)
Posted 9/14/2022 (updated 3/27/2024)
This fact sheet discusses new amendments to Tennessee’s naloxone access laws that went into effect on July 1, 2022. These amendments increase access to naloxone in several ways and remove some confusing language that previously limited the impact of state efforts to increase access to lifesaving opioid antagonist medications
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).
Posted 6/7/2022 (updated 3/27/2024)
Stigma and bias among community members, health care providers, and even family members toward individuals with substance use disorder negatively affects the care provided to this population. Stigma prevents individuals from seeking treatment and continues to divide them from their families, their communities, and the evidence-based treatments available.
Posted 4/6/2022 (updated 3/27/2024)
County jails and community organizations across Michigan are teaming up on a new approach to distribute naloxone (Narcan®), the lifesaving medication used to reverse an opioid overdose, through the use of customized vending machines.
Posted 3/22/2022 (updated 3/27/2024)
The purpose of this document is to provide detailed guidelines of the Nurse Care Manager Model of Office Based Addiction Treatment program for management of substance use disorders, with particular emphasis on treatment of opioid use disorder with buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations).
Posted 3/15/2022 (updated 3/27/2024)
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.
Posted 3/14/2022 (updated 3/27/2024)
Substance use and its progression to impairment, loss of control, and development of substance use disorders is a significant problem for adolescents and young adults. This presentation will provide an overview of developmentally-informed approaches to engaging youth and their families in treatment.
Learning Objectives:
Recognize motivational approaches to working with substance involved youth
Identify approaches to engaging families of substance involved youth
Speaker: Marc Fishman, MD